Deploying GenAI within regulatory frameworks

𝐀𝐈 𝐂𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐜𝐞 & 𝐃𝐚𝐭𝐚 𝐏𝐫𝐨𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐋𝐚𝐰𝐬 𝐟𝐨𝐫 𝐆𝐞𝐧𝐀𝐈 𝐀𝐩𝐩𝐬 Building GenAI Apps for a Global Audience?  Understanding Regional Data Protection and AI laws is not optional, it is foundational. Here is what you need to know: 1. UNDERSTANDING GLOBAL REGULATORY VARIANCE Building GenAI for a global audience requires understanding regional data protection and AI laws. Key Regulations by Region: • EU AI Act: Risk-based AI obligations for certain AI systems and transparency use cases • GDPR (EU): Transparency & Consent • DPDP (India): Digital Personal Data Protection • PIPL (China): Strict Data Localization • CCPA (California): Data Access & Opt-Out • LGPD (Brazil): Local Compliance Rules 2. IMPACT OF THESE REGULATIONS ON YOUR AI TRAINING DATA To build compliant GenAI apps,  Ensure that data used for training AI models follows the regional rules: Data Collection → Processing → Model Training → Deployment Three Core Requirements: a. User Consent: Obtain explicit consent for data collection and use b. Data Minimization: Collect only necessary data for the intended purpose c. Anonymization: Remove personally identifiable information from training data 3. MITIGATING AI ETHICS AND BIAS RISKS AI systems must be fair and ethical, particularly in high-risk areas: a. Fairness: Ensure your AI models don't discriminate, especially in areas like recruitment or finance. b. Bias Mitigation: Regularly test and adjust your models to reduce bias in the outputs. 4. ENSURING TRANSPARENCY IN AI MODEL DEVELOPMENT Transparency is a cornerstone of compliance, especially when your AI impacts users directly: a. Explainability: Protect data in transit and at rest. b. Consent Management: Collect, track, and manage user consent. c. Privacy by Design: Embed privacy into every system layer. 5. MANAGING CROSS-BORDER DATA FLOW GenAI apps often rely on data from various regions, so it's critical to understand data sovereignty laws: a. Data Sovereignty: Follow local laws on where data is stored and processed. b. Data Transfer Agreements: Use SCCs or BCRs for compliant cross-border transfers. THE COMPLIANCE CHECKLIST Before launching GenAI globally, verify: 1. Regional Compliance: • GDPR for EU? (Transparency & Consent) • DPDP for India? (Data Protection) • PIPL for China? (Data Localization) • CCPA for California? (Access & Opt-Out) • LGPD for Brazil? (Local Rules) 2. Training Data: • User consent obtained? • Data minimized? • PII anonymized? 3. Ethics & Bias: • Fairness tested? • Bias mitigation in place? 4. Transparency: • Explainability documented? • Consent management system? • Privacy by design? 5. Cross-Border: • Data sovereignty compliance? • Transfer agreements (SCCs/BCRs)? Each region has different requirements.  Build for the strictest, adapt for the rest. Which regulation applies to your GenAI app?

The FDA’s latest Executive Summary highlights a significant evolution in regulatory thinking for generative AI (#GenAI) devices. While previous guidance addressed AI broadly, this new approach focuses on the unique complexities of GenAI: + Foundation Models: Acknowledges challenges in managing and regulating third-party models that power GenAI, emphasizing the need for transparency and adaptability. + Non-Deterministic Outputs: Spotlights risks like "hallucinations," requiring stricter controls and tailored performance metrics. + Postmarket Monitoring: Proposes new strategies to address GenAI’s continuous learning and real-world variability. This marks a shift toward a more dynamic, lifecycle-based approach to ensure safety. What are the implications for entrepreneurs? Transparency is crucial—entrepreneurs must document their model's design, training data, and performance metrics, even when leveraging third-party foundation models. Narrowly defined use cases are equally important to ensure products are safely and effectively evaluated, mindful of the competing pressure to create applications with broad utility (and market potential). Startups should prioritize robust monitoring systems to track real-world performance, mitigate risks like bias or hallucinations, and maintain consistent outputs across diverse deployments. As always, human-in-the-loop safeguards and transparent, user-centric designs can enhance trust and safety. FDA’s lifecycle approach means compliance doesn’t stop at approval—continuous evaluation, updates, and monitoring will be increasingly expected to keep products aligned with regulatory and patient safety standards. Explore the full document for insights: https://lnkd.in/dXefRaaS #wearenina #healthcaretechnologies Nina Capital

FDA Halts Clearance of AI-Powered Diagnostic After Audit Reveals Missing Model Lineage Documentation.   This headline is hypothetical, but it captures exactly where the industry is heading. As #AI accelerates across life sciences, the FDA is shifting from passive observer to active policy-maker. Its message is unequivocal: #GenAI will scale only within a disciplined framework of audits, traceability, domain-qualified oversight, and documented technical competence.   In 2025, the FDA advanced its regulatory posture through landmark actions—deploying AI-assisted scientific reviews, piloting “agentic AI” inside its centers, and issuing major draft guidances including Artificial Intelligence and Machine Learning (AI/ML) in Drug and Biological Product Development (Draft Guidance 2023-0065) and Marketing Submission Recommendations for AI/ML-Enabled Device Software Functions (2023-0029). These documents outline how AI/ML outputs may support decisions for drugs, biologics, and devices.   The emerging rulebook anchors GenAI within established compliance regimes: GxP, 21 CFR Part 11, 21 CFR Part 820, ICH E6 (R3)/E8(R1), ISO 13485, ISO 14971, ISO/IEC 27001, and Good Machine Learning Practice (GMLP) co-authored with Health Canada and MHRA. Each framework reinforces requirements for qualified personnel, documented training, and role-based competency.   Central to this evolution is the Digital Health Advisory Committee (DHAC), the FDA’s dedicated advisory body for AI. DHAC now shapes policy, evaluates risk, and defines governance expectations for adaptive systems—signaling the agency’s need for specialized reviewers and durable oversight structures.   Across guidances, one theme dominates: [AI must be explainable, validated, and audit-ready]. LLMs influencing clinical, safety, manufacturing, or diagnostic decisions must maintain documented data lineage, validated training datasets (ICH E9), model-version controls, reproducible MLOps pipelines, role-based access controls (21 CFR 11.10), and human-in-the-loop approvals. Continuous-learning models may adapt only through managed updates defined under the Predetermined Change Control Plan (PCCP).   This is not regulation catching up to innovation—it is regulation shaping innovation’s boundaries. The FDA is building a governance ecosystem where GenAI outputs must withstand forensic scrutiny: every inference traceable, every model audit-ready, every reviewer appropriately qualified. For #lifesciences, the implications are profound. #AI adoption now depends less on technical prowess and more on regulatory readiness: validated data pipelines, compliant MLOps, continuous monitoring, and documentation fit for FDA inspection.   As #AI becomes inseparable from R&D, manufacturing, and devices, the FDA’s emerging policy architecture will determine not just how fast companies innovate—but how safely therapies reach patients. In this era, responsible, qualification-anchored AI is not optional. It is a regulatory requirement.

McKinsey & Company 𝗮𝗻𝗮𝗹𝘆𝘇𝗲𝗱 𝟭𝟱𝟬+ 𝗲𝗻𝘁𝗲𝗿𝗽𝗿𝗶𝘀𝗲 𝗚𝗲𝗻𝗔𝗜 𝗱𝗲𝗽𝗹𝗼𝘆𝗺𝗲𝗻𝘁𝘀 — 𝗮𝗻𝗱 𝗳𝗼𝘂𝗻𝗱 𝗼𝗻𝗲 𝗰𝗼𝗺𝗺𝗼𝗻 𝘁𝗵𝗿𝗲𝗮𝗱: ⬇️ One-off solutions don’t scale. The most successful projects take a different path: They use open, modular architectures that enable speed, reuse, and control. → Designed for reuse → Able to plug in best-in-class capabilities → Free from vendor lock-in This is the reference architecture McKinsey now recommends — optimized to scale what works while staying compliant. It consists of five core components: ⬇️ 𝟭. 𝗦𝗲𝗹𝗳-𝘀𝗲𝗿𝘃𝗶𝗰𝗲 𝗽𝗼𝗿𝘁𝗮𝗹: → A secure, compliant “pane of glass” where teams can launch, monitor, and manage GenAI apps. → Preapproved patterns, validated capabilities, shared libraries. → Observability and cost controls built-in. 𝟮. 𝗢𝗽𝗲𝗻 𝗮𝗿𝗰𝗵𝗶𝘁𝗲𝗰𝘁𝘂𝗿𝗲 → Services are modular, reusable, and provider-agnostic. → Core functions like RAG, chunking, or prompt routing are shared across apps. → Infra and policy as code, built to evolve fast. 𝟯. 𝗔𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗴𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 𝗴𝘂𝗮𝗿𝗱𝗿𝗮𝗶𝗹𝘀 → Every prompt and response is logged, audited, and cost-attributed. → Hallucination detection, PII filters, bias audits — enforced by default. → LLMs accessed only through a centralized AI gateway. 4. 𝗙𝘂𝗹𝗹-𝘀𝘁𝗮𝗰𝗸 𝗼𝗯𝘀𝗲𝗿𝘃𝗮𝗯𝗶𝗹𝗶𝘁𝘆 → Centralized logging, analytics, and monitoring across all solutions → Built-in lifecycle governance, FinOps, and Responsible AI enforcement → Secure onboarding of use cases and private data controls → Enables policy adherence across infrastructure, models, and apps 5. 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻-𝗴𝗿𝗮𝗱𝗲 𝗨𝘀𝗲 𝗖𝗮𝘀𝗲𝘀 → Modular setup for user interface, business logic, and orchestration → Integrated agents, prompt engineering, and model APIs → Guardrails, feedback systems, and observability built into the solution → Delivered through the AI Gateway for consistent compliance and scale The message is clear: If your GenAI program is stuck, don’t look at the LLM. Look at your platform. 𝗜 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲𝘀𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀 — 𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝘁𝗵𝗲𝘆 𝗺𝗲𝗮𝗻 𝗳𝗼𝗿 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝘂𝘀𝗲 𝗰𝗮𝘀𝗲𝘀 — 𝗶𝗻 𝗺𝘆 𝘄𝗲𝗲𝗸𝗹𝘆 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿. 𝗬𝗼𝘂 𝗰𝗮𝗻 𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝗵𝗲𝗿𝗲 𝗳𝗼𝗿 𝗳𝗿𝗲𝗲: https://lnkd.in/dbf74Y9E

⚖️Generative AI in EU law 🔍 This paper serves as a critical analysis of the AI Act, identifying gaps and challenges in addressing the rapidly advancing applications of Generative AI. It provides recommendations to ensure the safe and compliant deployment of LLMs. 🚀 Regarding liability: 🎯 Benefits The Product Liability Directive and AILD provide valuable structures for addressing liability in GenAI applications by recognizing the potential liability from post-deployment learning. This scope supports claims for damages, including rights violations, and addresses AI opacity and information asymmetry between providers and users. Both directives shift the burden of proof, requiring providers to disclose relevant information if harm is suspected. 🎯Gaps Both directives rely on the AI Act, which has limitations when applied to General-Purpose AI (GPAI) models. Initially, the AI Act classified GPAI as high-risk by default, but it has since adopted a 'systemic risk' approach. Yet, it lacks clear criteria for defining societal risks specific to GPAI, creating ambiguity around liability and making it challenging to determine the conditions under which GenAI falls within AILD’s scope. 🎯 Recommendations for a Tailored Code of Practice (CoP) The authors recommend establishing a CoP for GPAI models presenting systemic risks. This CoP would clarify the model’s compliance with the AI Act and provide a framework for risk management specific to GenAI. Extending the disclosure mechanism and rebuttable presumption of causation to all GPAI models would also enhance accountability, as GenAI developers typically possess incident-relevant information and should be obligated to share it. 🎯Clarifying Model Development and Data Intent The lack of a singular purpose in GenAI models complicates risk prediction and compliance assessments as required by the AI Act. To manage risks more effectively, the authors propose emphasizing criteria such as model scalability, input diversity, and transparent data usage objectives. For models trained on restricted datasets that rely on few/zero-shot learning capabilities, developers may need to disclose auxiliary information, thereby clarifying links between observed and unobserved object classes and aligning with transparency goals. 🎯Incorporating Ethical and Technical Safeguards The paper suggests combining conventional fault criteria with additional ethical and technical safeguards within the CoP. These would guide GenAI developers to: 🔸 Enhance Data Transparency: Document data intent and collection methods. 🔸 Ensure Data Quality: Construct representative datasets of sufficient quality, reducing risks of overfitting and increasing generalizability. 🔸 Implement (Pro)Active Monitoring: Includes reporting potential harm incidents and forming alliances with credible third-party organizations for validation and evidence access. 🔗 https://lnkd.in/dERy5n9u #AI #AIAct

Today's #sundAIreads is about the regulatory and liability implications of modifying general-purpose AI (#GPAI) models. The reading in question is "The Regulation of Fine-Tuning: Federated Compliance for Modified GPAI Models" by Philipp Hacker and Matthias Holweg. ➡️ What is the range of GPAI modifications? The authors distinguish between six types of modifications: 1️⃣ Standard architecture: The original model remains unchanged, but is customized based on carefully designed prompts. 2️⃣ Hyperparameters: The original model remains unchanged, but its "temperature" is adjusted, i.e., whether it should focus on "exploration" (generating new responses) or "exploitation" (prioritizing precise answers). 3️⃣ Retrieval-augmented generation (#RAG): The base model architecture remains unchanged, but predictions are explicitly based on custom data repositories. 4️⃣ Custom GPTs: Sophisticated prompt engineering is combined with RAG to tailor GPAI models to specific domain applications. 5️⃣ Fine-tuning: New data is systematically introduced into the training to align model outputs with organizational preferences. 6️⃣ Distillation: Smaller, more efficient versions of larger models are created to facilitate deployment in resource-constrained environments. ➡️ Who should be liable for modifications? The authors argue that regulatory and civic liability should be "conditional on foreseeability and design scope." GPAI model providers should thus not be held liable for risks that "emerge solely from how the model is applied in a given user-defined context, except [...] where the provider has, e.g., failed to supply adequate instructions or warnings about known model limitations." Testing protocols should be bifurcated accordingly: 1️⃣ Test and document the behavior of the base model in a generic environment using standardized evaluation metrics. 2️⃣ Test the adapted model in the specific context for which it is intended using context-specific metrics. ➡️ What implications do GPAI model modifications have under the #AIAct? A combined reading of Art. 25(1) and Rec. 109 suggests that deployers can become providers of a modified model whenever a modification is "substantial" or even results in an entirely new model. A modification should be considered substantial in turn "where it significantly increases at least one relevant risk" to fundamental rights and "insubstantial when it merely enhances the model's behavior across several risk dimensions or worsens it in only one." In order to assess changes to the risk profile, the authors propose a compute and consequence scanning (CCS) test that combines the FLOP threshold with a functional risk analysis. In the remainder of the paper, the authors not only provide practical examples, but also an analysis of modifications under the new EU liability framework, as well as their view on the societal, policy, and managerial implications of their findings. The full paper is available here: https://bit.ly/4nktPKL.

Governance is doing the hard, boring things well—and doing them every day.  The hard work—and where programs often stall—is operational governance - turning principles into day‑to‑day controls, evidence, and accountability at scale. At Cognizant, we’ve learned that governance breaks down when teams can’t answer basic questions consistently: What data trained this model? Who approves changes? How are prompts, outputs, risks, and costs monitored in production? The answer isn’t more paperwork—it’s instrumentation, automation, and continuous assurance. Consider : Principles without a framework don’t stick. Responsible AI principles are necessary, but they only drive outcomes when they’re operationalized via a structured framework (think model inventory, lineage, roles, controls, telemetry, and audits). Compliance needs proof. Executives and regulators expect evidence that AI systems are governed in production (not just at launch). LLMs raise new governance needs. GenAI introduces prompt management, output reliability, cost controls, and IP/data‑use questions that traditional ML governance doesn’t cover. If your AI program feels stuck between policy and reality, it’s probably missing these building blocks: A single model & data registry with lineage, licenses, and usage rights Prompt logging & evaluation, tied to risk thresholds and escalation paths Automated control testing (privacy, safety, bias, reliability) running in production Clear roles & accountability (who approves, who monitors, who signs off) Telemetry & cost observability to keep outcomes, spend, and risk in balance

📢 New Memo: The General-Purpose AI (GPAI) Code of Practice translates the EU AI Act’s obligations into concrete measures across safety and security, transparency, and copyright. The Safety and Security chapter—which applies only to GPAI models with systemic risk (GPAISR)—requires signatories to meet the ‘state of the art’ (SOTA) for several of its most central provisions. A dynamic reference, SOTA is meant to future-proof the regulation, allowing risk management to evolve alongside the technology. Yet neither the AI Act nor the Code specifies how to determine which measures may qualify as SOTA, how to adjudicate competing claims, or when to update regulatory expectations in light of new evidence. In this memo, we address some of the challenges associated with using SOTA as a dynamic reference to the ‘forefront of relevant research, governance and technology.’ We argue that SOTA is best understood as a process-driven concept: it is not determined by provider practice alone, but established through scientific discourse within the broader expert ecosystem—including scholars, civil society, and independent experts. To make SOTA assessments structured and comparable, we propose three criteria grounded in EU legal precedent: availability (technically feasible, not aspirational), proportionality (balancing effectiveness against burden), and verifiability (open to independent scrutiny). Making SOTA operational requires an appropriate institutional process. We propose a three-step framework: (1) monitoring gaps in current risk management; (2) enabling innovation and evidence sharing from any actor in the ecosystem; (3) and formal assessment and communication by the AI Office supported by the Scientific Panel. Luise Eder, Amin Oueslati, Robin Staes-Polet, Ze Shen Chin, Jimmy Farrell, Bruno Galizzi, Toni Lorente, Nada Madkour, PhD, Jessica Newman, Henry Papadatos, Lama Saouma, Lisa Soder, Risto Uuk, Anna Katariina Wisakanto, Marta Ziosi, Robert Trager Oxford Martin AI Governance Initiative

This landmark publication by the FDA's OC in JAMA illuminates the way forward in the oversight of clinical Generative AI (GenAI) solutions. The FDA leaders underscore the potential risks associated with these solutions while acknowledging their statutory limitations in regulating a technology that is profoundly affected by the context in which it operates. Check key excerpts from the FDA article: " …as that (Pre-Cert) program demonstrated, successfully developing and implementing such (Total Product Life Cycle) pathways may require the FDA to be granted new statutory authorities. The sheer volume of these changes and their impact also suggest the need for industry and other external stakeholders to ramp up assessment and quality management of AI across the larger ecosystem beyond the remit of the FDA." "The complexity of LLMs and the permutations of outputs necessitate oversight from individuals and institutions in addition to regulatory authorities. Because we cannot unduly burden individual clinicians with such oversight, there is a need for specialized tools that enable better assessment of LLMs in the contexts and settings in which they will be used." "Given the capacity for 'unlocked' models to evolve and AI’s sensitivity to contextual changes, it is becoming increasingly evident that AI performance should be monitored in the environment in which it is being used. ... The tools and circumstances of this ongoing evaluation must be recurrent and as close to continuous as possible, and the evaluation should be in the clinical environment in which it is being used." "Currently, however, neither the development community nor the clinical community is fully equipped for the recurrent, local assessment of AI throughout its life cycle. Health systems could fill this role, but currently their clinical information systems are unable to monitor the ongoing and long-term safety and effectiveness of these interventions." We agree that the way forward for overseeing clinical GenAI solutions will require a shift from a purely centralized regulatory model to a hybrid one that incorporates local, context-specific monitoring with a ground-level risk mitigation approach. Health systems can be equipped and incentivized to become widely distributed GenAI safety, effectiveness, and alignment sentinels using ISO 42001-certified AI Management Systems (AIMS). The pre-print articles linked in the comments detail how mutual assurance based on certified AIMS can become a foundation for clinical GenAI oversight. This is the adaptive approach we need to safely harness GenAI's potential in healthcare at scale. FDA Troy Tazbaz Robert Califf Haider Warraich ISO/IEC Artificial Intelligence (AI) Assistant Secretary for Technology Policy ANAB - ANSI National Accreditation Board U.S. Department of Veterans Affairs Coalition for Health AI (CHAI) Health AI Partnership National Institute of Standards and Technology (NIST) #GenAI #AIRegulation #AIMS #ISO42001 #AISafety

😅 The FDA Digital Health Advisory committee meeting yesterday was great. I actually wrote some concrete implementation strategy for concepts presented yesterday about one year ago! Here are some of my go to tools for getting a novel GenAI-enabled medical device FDA cleared: ➡️ Scope the device narrowly. Keep the “regulated core” minimal, often just the AI algorithm, and classify everything else as MDDS or general-purpose software. ➡️ Anchor your foundation model in specific, clinical endpoints. Broad, flexible LLMs make the FDA nervous; mapping them to concrete medical claims helps reviewers understand intended use and risk. ➡️ Start with an exploratory Pre-Sub. It’s the best way to learn what the FDA considers “too general” or “too adaptive” early, before you’ve spent months building validation datasets that won’t fly. ➡️ Plan for a PCCP early. If your model will evolve post-market, design a clear “change control” boundary now instead of after the first update. ➡️ Ground validation in realism, not perfection. Use representative clinical data, define clear acceptance criteria, and justify your test metrics the same way you would for any traditional AI/ML SaMD. Got a GenAI enabled medical device you would like to get FDA cleared? Reach out. Let's do it! #MedTech #SaMD #FDAClearance #510k #ClinicalAI #RegulatoryAffairs #DigitalHealth #MedicalImagingAI #generativeai #chatgpt